Isracann Biosciences Inc.
ISCNF
$0.00
$0.000.00%
OTC PK
| 08/31/2022 | 05/31/2022 | 02/28/2022 | 11/30/2021 | 08/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -44.23% | -50.09% | -71.59% | -14.70% | -37.95% |
| Depreciation & Amortization | -3.57% | -15.46% | 7.89% | 12.16% | 15.07% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.37% | -49.67% | -71.18% | -14.46% | -37.33% |
| Operating Income | 43.37% | 49.67% | 71.18% | 14.46% | 37.33% |
| Income Before Tax | 34.88% | 87.83% | 62.59% | 31.78% | -131.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.88% | 87.84% | 62.59% | 31.78% | -131.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.88% | 87.84% | 62.59% | 31.78% | -101.93% |
| EBIT | 43.37% | 49.67% | 71.18% | 14.46% | 37.33% |
| EBITDA | 44.23% | 50.09% | 71.59% | 14.70% | 37.95% |
| EPS Basic | 42.31% | 88.38% | 65.63% | 36.00% | -85.71% |
| Normalized Basic EPS | 43.75% | 62.79% | 65.00% | 36.17% | 0.00% |
| EPS Diluted | 42.31% | 88.38% | 65.63% | 36.00% | -85.71% |
| Normalized Diluted EPS | 43.75% | 62.79% | 65.00% | 36.17% | 0.00% |
| Average Basic Shares Outstanding | 8.47% | 4.87% | 7.43% | 8.08% | 8.14% |
| Average Diluted Shares Outstanding | 8.47% | 4.87% | 7.43% | 8.08% | 8.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |